BioSpace News Archive

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63rd Annual Meeting and Exposition of the American Society of Hematology.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that the Company will be added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 20, 2021.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), today announced new data highlighting the clinical utility of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).

Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of $160 million.

Centessa Pharmaceuticals plc, a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced that it has been added to the NASDAQ Biotechnology Index.

Endogena Therapeutics Inc., an endogenous regenerative therapeutics company, today announced that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treatments targeting degenerative diseases of the eye.

Arcellx, Inc., a privately held clinical-stage biopharmaceutical company, today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease in patients receiving allogeneic hematopoietic cell transplantation.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a Phase 1 study of GBT021601 (GBT601).

Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed/refractory hematologic malignancies at the 63rd American Society of Hematology (ASH) Annual Meeting.